Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia.

Abstract

Previous studies reported controversial results concerning alterations of astrocytes in schizophrenia. Because S100B may be regarded as a marker for astrocytes, the objective of this study was to examine S100B serum concentrations in 30 patients with schizophrenia with a monoclonal two-site immunoluminometric assay that specifically detects S100B. An ANOVA revealed medication (p<0.005) and deficit vs. nondeficit syndrome (p<0.05) as factors that influenced S100B significantly. S100B was higher in schizophrenic patients treated with antipsychotic drugs for approximately 3 weeks (241.1+/-152.5 ng/l) in comparison with unmedicated patients (111.4+/-31.8 ng/l, p<0.005), and healthy age-matched controls (112.8+/-53.4 ng/l, p<0.001; Bonferroni corrected two-tailed Student's t-test). There was no difference of S100B between unmedicated patients and controls (p>0.05). Patients with deficit (250.6+/-154.9 ng/l) had higher S100B levels than patients with nondeficit schizophrenia (146.7+/-107.2 ng/l, p<0.05) or controls (p<0.005). S100B was positively correlated with the subscore 'thought disturbance' of the Brief Psychiatric Rating Scale (p<0.05). In summary, increased serum levels of S100B may indicate alterations of astrocytes during early treatment with antipsychotics and in deficit schizophrenia. Whether S100B is elevated due to injured astrocytes and a disrupted blood-brain barrier, or by active secretion of S100B by astrocytes, has to be clarified by further studies.

• Authors: Matthias L Schroeter, Hashim Abdul-Khaliq, Stephan Frühauf, Ruth Höhne, Gabi Schick, Albert Diefenbacher, Ingolf E Blasig
• Journal: Schizophrenia research (Schizophr Res) Vol. 62 Issue 3 Pg. 231-6 (Aug 01 2003) ISSN: 0920-9964 [Print] Netherlands
• PMID: 12837519 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antipsychotic Agents
• Biomarkers
• Nerve Growth Factors
• S100 Calcium Binding Protein beta Subunit
• S100 Proteins
• S100B protein, human

Topics

• Adult
• Analysis of Variance
• Antibodies, Monoclonal (metabolism)
• Antipsychotic Agents (adverse effects)
• Astrocytes (metabolism)
• Biomarkers
• Blood-Brain Barrier (metabolism)
• Cognition Disorders (diagnosis, etiology)
• Female
• Humans
• Male
• Nerve Growth Factors (blood, metabolism)
• S100 Calcium Binding Protein beta Subunit
• S100 Proteins (blood, metabolism)
• Schizophrenia (blood, complications, drug therapy)
• Severity of Illness Index